Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (6): 336-341.doi: 10.3760/cma.j.cn371439-20230214-00067
• Original Articles • Previous Articles Next Articles
Zhu Siyu1, Wang Xuehong2(), Li Wenqian1, Liu Shu1
Received:
2023-02-14
Revised:
2023-04-05
Online:
2023-06-08
Published:
2023-07-11
Contact:
Wang Xuehong,Email:Supported by:
Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341.
"
临床资料 | 对照组(n=40) | CAG组(n=40) | 胃癌组(n=40) | χ2/F值 | P值 |
---|---|---|---|---|---|
性别 | |||||
男 | 22(55.00) | 19(47.50) | 25(62.50) | 1.82 | 0.403 |
女 | 18(45.00) | 21(52.50) | 15(37.50) | ||
年龄(岁) | 54.85±8.35 | 55.50±11.35 | 58.20±7.68 | 1.48 | 0.234 |
BMI(kg/m2) | 22.24±3.19 | 21.88±1.98 | 22.58±2.53 | 0.96 | 0.389 |
吸烟 | |||||
无 | 24(60.00) | 23(57.50) | 19(47.50) | 1.41 | 0.493 |
有 | 16(40.00) | 17(42.50) | 21(52.50) | ||
饮酒 | |||||
无 | 26(65.00) | 23(57.50) | 20(50.00) | 1.84 | 0.398 |
有 | 14(35.00) | 17(42.50) | 20(50.00) |
"
临床特征 | 例数 | FABP1水平(ng/ml) | t/Z/F值 | P值 |
---|---|---|---|---|
性别 | ||||
男 | 25 | 66.76±17.30 | 0.98 | 0.333 |
女 | 15 | 72.03±14.87 | ||
年龄(岁) | ||||
<60 | 23 | 65.22±16.87 | 1.60 | 0.117 |
≥60 | 17 | 73.49±15.02 | ||
吸烟 | ||||
无 | 19 | 62.24±16.49 | 2.54 | 0.015 |
有 | 21 | 74.61±14.34 | ||
饮酒 | ||||
无 | 20 | 75.04(53.44,80.41) | 0.10 | 0.925 |
有 | 20 | 69.87(55.12,84.28) | ||
肿瘤直径(cm) | ||||
<5 | 33 | 66.92±17.17 | 2.23 | 0.035 |
≥5 | 7 | 77.28±8.99 | ||
肿瘤部位 | ||||
胃窦 | 16 | 64.40±18.08 | 1.06 | 0.356 |
贲门 | 10 | 69.59±13.24 | ||
胃体 | 14 | 73.08±16.36 | ||
分化程度 | ||||
低分化 | 24 | 67.43±16.94 | 0.61 | 0.545 |
中、高分化 | 16 | 70.70±15.99 | ||
浸润深度 | ||||
T1-2 | 19 | 72.54±15.40 | 1.41 | 0.166 |
T3-4 | 21 | 65.29±16.95 | ||
淋巴结转移 | ||||
无 | 10 | 55.72±15.77 | 3.22 | 0.003 |
有 | 30 | 73.07±14.43 | ||
远处转移 | ||||
无 | 31 | 72.62(48.76,79.03) | 1.96 | 0.050 |
有 | 9 | 82.78(61.15,90.86) | ||
TNM分期 | ||||
Ⅰ~Ⅱ期 | 24 | 72.62(52.38,79.49) | 0.66 | 0.508 |
Ⅲ~Ⅳ期 | 16 | 74.07(56.62,85.77) |
[1] |
Norwood DA, Montalvan EE, Dominguez RL, et al. Gastric cancer: emerging trends in prevention, diagnosis, and treatment[J]. Gastroenterol Clin North Am, 2022, 51(3): 501-518. DOI: 10.1016/j.gtc.2022.05.001.
doi: 10.1016/j.gtc.2022.05.001 |
[2] |
Wood SM, Gill AJ, Brodsky AS, et al. Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway[J]. Mod Pathol, 2017, 30(1): 123-133. DOI: 10.1038/modpathol.2016.170.
doi: 10.1038/modpathol.2016.170 |
[3] |
范海华, 刘燕文. FABP1在胃癌中的研究进展[J]. 东南大学学报(医学版), 2021, 40(2): 234-237. DOI: 10.3969/j.issn.1671-6264.2021.02.017.
doi: 10.3969/j.issn.1671-6264.2021.02.017 |
[4] |
Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, et al. Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(2): 272-280. DOI: 10.1158/1055-9965.EPI-05-0632.
doi: 10.1158/1055-9965.EPI-05-0632 |
[5] |
Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-349. DOI: 10.1038/s41571-023-00747-0.
doi: 10.1038/s41571-023-00747-0 pmid: 36959359 |
[6] |
Ku CY, Liu YH, Lin HY, et al. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma[J]. Oncotarget, 2016, 7(14): 18229-18246. DOI: 10.18632/oncotarget.7571.
doi: 10.18632/oncotarget.7571 |
[7] |
Zhang GL, Pan LL, Huang T, et al. The transcriptome difference between colorectal tumor and normal tissues revealed by single-cell sequencing[J]. J Cancer, 2019, 10(23): 5883-5890. DOI: 10.7150/jca.32267.
doi: 10.7150/jca.32267 |
[8] |
Sharaf RN, Butte AJ, Montgomery KD, et al. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes[J]. BMC Gastroenterol, 2011, 11: 5. DOI: 10.1186/1471-230X-11-5.
doi: 10.1186/1471-230X-11-5 pmid: 21251264 |
[9] |
Jiang Z, Shen H, Tang B, et al. Quantitative proteomic analysis reveals that proteins required for fatty acid metabolism may serve as diagnostic markers for gastric cancer[J]. Clin Chim Acta, 2017, 464: 148-154. DOI: 10.1016/j.cca.2016.11.032.
doi: S0009-8981(16)30486-7 pmid: 27884752 |
[10] |
Mukai T, Egawa M, Takeuchi T, et al. Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease[J]. FEBS Open Bio, 2017, 7(7): 1009-1016. DOI: 10.1002/2211-5463.12240.
doi: 10.1002/2211-5463.12240 pmid: 28680813 |
[11] |
Shi J, Zhang Y, Gu W, et al. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults[J]. PLoS One, 2012, 7(11): e48777. DOI: 10.1371/journal.pone.0048777.
doi: 10.1371/journal.pone.0048777 |
[12] |
岳晓倩, 邵丽春. 幽门螺旋杆菌感染与血脂增高代谢方面的关系[J]. 中国社区医师, 2021, 37(26): 73-74. DOI: 10.3969/j.issn.1007-614x.2021.26.035.
doi: 10.3969/j.issn.1007-614x.2021.26.035 |
[13] |
Hellerstein MK, Benowitz NL, Neese RA, et al. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers[J]. J Clin Invest, 1994, 93(1): 265-272. DOI: 10.1172/JCI116955.
doi: 10.1172/JCI116955 pmid: 8282797 |
[14] |
姚俊秀, 肖毅, 王强, 等. 肝脏因子FABP1与血脂异常的相关性分析[J]. 解放军医学杂志, 2021, 46(6): 580-586. DOI: 10.11855/j.issn.0577-7402.2021.06.08.
doi: 10.11855/j.issn.0577-7402.2021.06.08 |
[15] |
刘松意. FABP1和TRIB3在不同胃疾病中的表达及其相关功能分析[D]. 沈阳: 中国医科大学, 2021. DOI: 10.27652/d.cnki.gzyku.2021.000902.
doi: 10.27652/d.cnki.gzyku.2021.000902 |
[1] | Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[7] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[8] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[9] | Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[10] | Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[11] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[12] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[13] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281. |
[14] | Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728. |
[15] | Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||